Electromagnetic Field Stimulation Therapy for Alzheimer's Disease.

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative dementia worldwide. AD is a multifactorial disease that causes a progressive decline in memory and function precipitated by toxic beta-amyloid (Aβ) proteins, a key player in AD pathology. In 2022, 6.5 million Americans lived with AD, costing the nation $321billion. The standard of care for AD treatment includes acetylcholinesterase inhibitors (AchEIs), NMDA receptor antagonists, and monoclonal antibodies (mAbs). However, these methods are either: 1) ineffective in improving cognition, 2) unable to change disease progression, 3) limited in the number of therapeutic targets, 4) prone to cause severe side effects (brain swelling, microhemorrhages with mAb, and bradycardia and syncope with AchEIs), 5) unable to effectively cross the blood-brain barrier, and 6) lack of understanding of the aging process on the disease. mAbs are available to lower Aβ, but the difficulties of reducing the levels of the toxic Aβ proteins in the brain without triggering brain swelling or microhemorrhages associated with mAbs make the risk-benefit profile of mAbs unclear. A novel multitarget, effective, and safe non-invasive approach utilizing Repeated Electromagnetic Field Stimulation (REMFS) lowers Aβ levels in human neurons and memory areas, prevents neuronal death, stops disease progression, and improves memory without causing brain edema or bleeds in AD mice. This REMFS treatment has not been developed for humans because current EMF devices have poor penetration depth and inhomogeneous E-field distribution in the brain. Here, we discussed the biology of these effects in neurons and the design of optimal devices to treat AD.

AI evidence extraction

Main findings

The article discusses repeated electromagnetic field stimulation (REMFS) as a non-invasive therapeutic approach for Alzheimer's disease, describing reported effects including lowering Aβ levels, preventing neuronal death, stopping disease progression, and improving memory in AD mice without causing brain edema or bleeds. It notes REMFS has not been developed for humans due to limitations of current EMF devices (poor penetration depth and inhomogeneous E-field distribution) and discusses biology and optimal device design.

Outcomes measured

• beta-amyloid (Aβ) levels
• neuronal death
• disease progression
• memory/cognition
• brain edema
• microhemorrhages
• EMF device penetration depth
• E-field distribution in brain

Limitations

• Appears to be a narrative discussion/review rather than a human clinical study; no human efficacy data are presented in the abstract.
• Key exposure parameters (frequency, intensity/SAR, dosing) are not provided in the abstract.
• Findings referenced include animal and human neuron results, but specific study designs, sample sizes, and quantitative results are not described.

{
    "study_type": "review",
    "exposure": {
        "band": null,
        "source": "therapeutic device (Repeated Electromagnetic Field Stimulation; REMFS)",
        "frequency_mhz": null,
        "sar_wkg": null,
        "duration": null
    },
    "population": null,
    "sample_size": null,
    "outcomes": [
        "beta-amyloid (Aβ) levels",
        "neuronal death",
        "disease progression",
        "memory/cognition",
        "brain edema",
        "microhemorrhages",
        "EMF device penetration depth",
        "E-field distribution in brain"
    ],
    "main_findings": "The article discusses repeated electromagnetic field stimulation (REMFS) as a non-invasive therapeutic approach for Alzheimer's disease, describing reported effects including lowering Aβ levels, preventing neuronal death, stopping disease progression, and improving memory in AD mice without causing brain edema or bleeds. It notes REMFS has not been developed for humans due to limitations of current EMF devices (poor penetration depth and inhomogeneous E-field distribution) and discusses biology and optimal device design.",
    "effect_direction": "unclear",
    "limitations": [
        "Appears to be a narrative discussion/review rather than a human clinical study; no human efficacy data are presented in the abstract.",
        "Key exposure parameters (frequency, intensity/SAR, dosing) are not provided in the abstract.",
        "Findings referenced include animal and human neuron results, but specific study designs, sample sizes, and quantitative results are not described."
    ],
    "evidence_strength": "insufficient",
    "confidence": 0.7399999999999999911182158029987476766109466552734375,
    "peer_reviewed_likely": "yes",
    "keywords": [
        "Alzheimer's disease",
        "Repeated Electromagnetic Field Stimulation",
        "REMFS",
        "beta-amyloid",
        "neurons",
        "device design",
        "penetration depth",
        "E-field distribution",
        "non-invasive therapy"
    ],
    "suggested_hubs": []
}

Comments

Log in to comment.

No comments yet.